Paul Scigalla
Overview
Explore the profile of Paul Scigalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geven C, Blet A, Kox M, Hartmann O, Scigalla P, Zimmermann J, et al.
BMJ Open
. 2019 Feb;
9(2):e024475.
PMID: 30782906
Introduction: Sepsis remains a major health problem with an increasing incidence, high morbidity and high mortality. Apart from treatment with antibiotics and organ support, no approved specific adjunct therapies currently...
2.
Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman B, Blet A, et al.
Crit Care
. 2018 Dec;
22(1):354.
PMID: 30583748
Background: Adrenomedullin (ADM) regulates vascular tone and endothelial permeability during sepsis. Levels of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a direct relationship with...
3.
Moehler M, Mahlberg R, Heinemann V, Obermannova R, Kubala E, Melichar B, et al.
Gastric Cancer
. 2016 Jun;
20(2):358-367.
PMID: 27255289
Background: This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS). Methods: Patients aged ≥18 ...
4.
Mebazaa A, Laterre P, Russell J, Bergmann A, Gattinoni L, Gayat E, et al.
J Intensive Care
. 2016 Apr;
4:24.
PMID: 27034779
Substantial attention and resources have been directed to improving outcomes of patients with critical illnesses, in particular sepsis, but all recent clinical trials testing various interventions or strategies have failed...
5.
Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske A, Lipp R, et al.
Invest New Drugs
. 2011 Apr;
30(3):1184-92.
PMID: 21484249
Purpose: S-1, an oral fluoropyrimidine derivative, has previously demonstrated anticancer efficacy in pancreatic cancer (PC), predominantly in Asian populations. This study evaluated the antitumor effect and safety of S-1 in...
6.
Bernhardt W, Wiesener M, Scigalla P, Chou J, Schmieder R, Gunzler V, et al.
J Am Soc Nephrol
. 2010 Dec;
21(12):2151-6.
PMID: 21115615
The reasons for inadequate production of erythropoietin (EPO) in patients with ESRD are poorly understood. A better understanding of EPO regulation, namely oxygen-dependent hydroxylation of the hypoxia-inducible transcription factor (HIF),...
7.
Wiecek A, Ahmed I, Scigalla P, Koytchev R
Adv Ther
. 2010 Oct;
27(12):941-52.
PMID: 20972656
Introduction: epoetin zeta is a recently introduced recombinant erythropoietin, designed to be biologically similar to epoetin alfa. This posthoc analysis evaluated the impact of switching patients with chronic kidney disease...
8.
Krivoshiev S, Todorov V, Manitius J, Czekalski S, Scigalla P, Koytchev R
Curr Med Res Opin
. 2008 Apr;
24(5):1407-15.
PMID: 18394266
Objective: To assess the therapeutic equivalence of epoetin zeta and epoetin alpha for correction of haemoglobin (Hb) concentration in patients with anaemia and chronic kidney disease (CKD) stage 5 maintained...
9.
Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R
Curr Med Res Opin
. 2008 Jan;
24(3):625-37.
PMID: 18208642
Objective: To evaluate the therapeutic efficacy and safety of epoetin zeta, compared with epoetin alfa, in maintaining target haemoglobin (Hb) concentrations in patients with anaemia and chronic kidney disease (CKD)...
10.
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al.
J Clin Oncol
. 2005 Nov;
24(1):25-35.
PMID: 16314617
Purpose: To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies. Patients And...